Crispr Therapeutics AG (NASDAQ:CRSP) — Stock Price
Crispr Therapeutics AG (NASDAQ:CRSP) is currently trading at $53.51 USD, down 0.02% today. Over the past 52 weeks, shares have ranged between $44.34 and $76.78. This page tracks Crispr Therapeutics AG's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CRSP market cap.
Crispr Therapeutics AG (CRSP) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Crispr Therapeutics AG's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Crispr Therapeutics AG Income Statement — Revenue, Profit & Earnings by Year
Crispr Therapeutics AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $3.51 Million | $35.00 Million | $370.00 Million | $436.00K | $913.08 Million |
| Cost of Revenue | $232.96 Million | $110.25 Million | $130.25 Million | $110.25 Million | $101.18 Million |
| Gross Profit | $-229.45 Million | $-75.25 Million | $239.75 Million | $-109.81 Million | $913.08 Million |
| Research & Development | $265.33 Million | $320.65 Million | $387.33 Million | $461.64 Million | $438.63 Million |
| SG&A | $73.54 Million | $72.98 Million | $76.16 Million | $102.46 Million | $102.80 Million |
| Total Operating Expenses | $338.87 Million | $391.32 Million | $462.29 Million | $563.35 Million | $539.55 Million |
| Operating Income | $-568.32 Million | $-466.57 Million | $-222.54 Million | $-673.16 Million | $373.53 Million |
| EBITDA | $-548.84 Million | $-447.31 Million | $-202.70 Million | $-648.99 Million | $391.48 Million |
| EBIT | $-568.32 Million | $-466.57 Million | $-222.54 Million | $-673.16 Million | $373.53 Million |
| Interest Expense | — | — | — | $46.83 Million | $23.96 Million |
| Income Before Tax | $-577.97 Million | $-362.67 Million | $-150.72 Million | $-650.50 Million | $379.53 Million |
| Income Tax Expense | $3.63 Million | $3.59 Million | $2.89 Million | $-325.00K | $1.87 Million |
| Net Income | $-581.60 Million | $-366.25 Million | $-153.61 Million | $-650.17 Million | $377.66 Million |
Crispr Therapeutics AG Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Crispr Therapeutics AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $2.27 Billion | $2.24 Billion | $2.23 Billion | $2.24 Billion | $2.75 Billion |
| Total Current Assets | $1.99 Billion | $1.94 Billion | $1.91 Billion | $1.85 Billion | $2.42 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $1.63 Billion | $1.61 Billion | $1.30 Billion | $1.60 Billion | $1.46 Billion |
| Net Receivables | $0.00 | $25.00 Million | $200.00 Million | $11.20 Million | $305.00K |
| Inventory | — | — | — | $-11.20 Million | — |
| Property, Plant & Equipment | — | — | — | $163.63 Million | $137.57 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $343.43 Million | $309.95 Million | $346.77 Million | $367.58 Million | $352.42 Million |
| Total Current Liabilities | $149.12 Million | $87.78 Million | $108.79 Million | $121.11 Million | $119.88 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $39.73 Million | $-74.56 Million | $-150.84 Million | $32.14 Million | $-698.00 Million |
| Total Stockholder Equity | $1.92 Billion | $1.93 Billion | $1.88 Billion | $1.88 Billion | $2.40 Billion |
| Retained Earnings | $-1.95 Billion | $-1.37 Billion | $-999.70 Million | $-846.09 Million | $-195.91 Million |
Crispr Therapeutics AG Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Crispr Therapeutics AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-345.01 Million | $-142.77 Million | $-260.38 Million | $-495.74 Million | $538.97 Million |
| Capital Expenditures | $914.00K | $1.90 Million | $9.47 Million | $37.19 Million | $81.70 Million |
| Free Cash Flow | $-345.93 Million | $-144.68 Million | $-269.85 Million | $-532.93 Million | $457.27 Million |
| Investing Cash Flow | $-31.80 Million | $-280.48 Million | $374.65 Million | $-258.65 Million | $-1.04 Billion |
| Financing Cash Flow | $426.03 Million | $331.98 Million | $62.66 Million | $38.59 Million | $250.94 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $72.50 Million | $86.57 Million | $81.03 Million | $97.95 Million | $102.39 Million |
| Depreciation | $19.48 Million | $19.26 Million | $19.84 Million | $24.17 Million | $17.95 Million |
| Change in Cash | $49.30 Million | $-91.29 Million | $177.59 Million | $-715.88 Million | $-245.52 Million |
Crispr Therapeutics AG Earnings History — EPS Actual vs. Analyst Estimates
Track Crispr Therapeutics AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 11, 2026 | -1.28 | -1.10 | -16.36% |
| Feb 17, 2026 | -1.37 | -1.17 | -17.09% |
| Nov 05, 2025 | -1.17 | -1.31 | +10.69% |
| Aug 04, 2025 | -1.29 | -1.40 | +7.86% |
| May 06, 2025 | -1.58 | -1.28 | -23.44% |
| Feb 11, 2025 | -0.44 | -1.19 | +62.89% |
| Nov 05, 2024 | -1.01 | -1.40 | +27.86% |
| Aug 05, 2024 | -1.49 | -1.52 | +1.97% |